A position statement on NAFLD/NASH based on the EASL 2009 special conference.

By V. Ratziu, S. Bellentani, H. Cortez‐Pinto, C. Day, Giulio Marchesini. Journal of Hepatology, 2010

1,090 citations recorded by the source corpus.

Universite Pierre et Marie Curie Paris VI, Assistance Publique Hopitaux de Paris, INSERM UMRS 893, France; Centro Studi Fegato, Gastroenterologia, Distretto di Carpi, Azienda USL di Modena, Italy; Departamento de Gastrenterologia, Unidade de Nutricao e Metabolismo, Hospital Universitario de Santa Maria, Instituto de Medicina Molecular, Lisbon, Portugal; Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom; Alma Mater Studiorum, Unit of Metabolic Diseases and Clinical Dietetics, University of Bologna, Italy

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/9ef072b21128e31a9f841d5a2afb8d5ca13e3c33

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. J. Clark
2. M. Pinzani
3. E. Tsochatzis
4. E. Buzzetti
5. D. Ehrmann

In Epidemiology

1. V. Ratziu
2. J. Clark
3. M. Pinzani
4. E. Tsochatzis
5. A. McCullough
6. E. Buzzetti
7. J. Lavine
8. N. Chalasani

In Pathology and Forensic Medicine

1. J. Clark
2. M. Pinzani
3. A. McCullough
4. Y. Kawano
5. D. Cohen

Citations in the corpus

• Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. (2013, background): “Although the “gold standard” for diagnosing and staging NAFLD is histology, abdominal unltrasonography allows its detection (4, 5).”
• The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). (2016, background): “[4] Ratziu V, Bellentani S, Cortez-Pinto H, et al.”
• Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline (2013, background): “Primary NAFLD/NASH is most commonly associated with IR and its phenotypic manifestations (145).”
• ENDPOINTS AND CLINICAL TRIAL DESIGN FOR NONALCOHOLIC STEATOHEPATITIS (2011, background): “These have been reviewed in the literature and will not be discussed at length here.(1,4,19,31-34) There is broad consensus that the following groups should be targeted for treatment (in order of clinical and public health significance): (1) subjects with the greatest risk of progression to cirrhosi”